Plain-English translation of NCT05871892 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether two advanced imaging scans—18F-FDGal PET/CT and 18F-FDGal PET/MRI—can better detect liver cancer and spot if it has spread to other parts of the body. These scans use a special tracer (a harmless radioactive substance) that the liver absorbs differently than other tissues, which may help doctors see cancer more clearly. The study aims to see if these new scans are better than the standard imaging tests doctors currently use.
Current imaging tests used to diagnose liver cancer don't always catch all cases, especially small tumors or cancer that has spread elsewhere in the body. This study exists to find out whether this new imaging technology could help doctors detect liver cancer earlier and more accurately, which could improve treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive one or both of the new imaging scans (PET/CT or PET/MRI) at a hospital in Aarhus, Denmark. The scan involves receiving a small injection of a harmless tracer substance, waiting a short time, and then lying still inside the scanner for imaging. The study team will use these scans to help evaluate whether you have liver cancer, how advanced it is, and whether it has spread—and to compare how well the new scans work compared to standard imaging.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Denmark
Sponsor
University of Aarhus
Enrollment target
~125 participants
Started
September 2023
Primary completion
April 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mona Kristiansen, MD
University of Aarhus
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.